News | November 22, 2022
Merck to acquire Imago BioSciences for $1.35 bn
Acquisition expands Merck’s growing hematology portfolio
Acquisition expands Merck’s growing hematology portfolio
Omicron BA.5 continues to be the most prevalent sublineage in the United States (nearly 30% of cases) at the time of publication of the data
Program will fight the rising incidence of antimicrobial (drug) resistance and improve patient outcomes
Zydus becomes the only Indian oncology player to venture into prognosis and diagnosis along with treatment planning
India is home to nearly 80 million diabetics and this number is expected to rise to a staggering 134 million in the next 25 years.
Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market
PIKA COVID-19 vaccine is currently in Phase 3, multi-country, multi-center clinical trial conducted at Southeast Asian and Middle East countries.
First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe
Viehbacher brings extensive international experience in large pharmaceutical and entrepreneurial biotech companies
The team will assist the State Health Authorities in instituting public health measures and facilitate operationalization of requisite control and containment measures
Subscribe To Our Newsletter & Stay Updated
